| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_268be9afa00cf55b5aa72b1612151ecb |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-127 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7068
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39541
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-127
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2818 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-127
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7068
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-28 |
| filingDate |
2019-06-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2022-08-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_82a4df40f58a77a05ebaea69cbf74623
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_987343007387d130aea06d6bd00168c6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_76cb9dba3d445bfb0be3508a1aa03689
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e09b4ef241f0feacbf43f5c93bc228a4 |
| publicationDate |
2022-08-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
AU-2019288048-B2 |
| titleOfInvention |
Combined medicine comprising gemcitabine-encapsulated liposome composition and immune checkpoint blockade |
| abstract |
The present invention addresses the problem of providing a medicine prepared by combining a liposome composition with an immune checkpoint blockade, wherein gemcitabine is encapsulated in a dissolved state in liposomes in the liposome composition. According to the present invention, a medicine which is a combination of (A) a liposome composition with (B) an immune checkpoint blockade is provided, wherein the liposome composition comprises liposomes each having an inner aqueous phase and an aqueous solution constituting an outer aqueous phase and having the liposomes dispersed therein, gemcitabine is encapsulated in a dissolved state in the liposomes, and the liposome composition and the immune checkpoint blockade are administered simultaneously or sequentially. |
| priorityDate |
2018-06-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |